Importantly, in multiple clinical studies of prostate cancer patients, the HSD3B1 CC genotype predicts poor responses to hormone therapies and increased prostate cancer-specific mortality [2,5,6]. This evidence concerns the gene HSD3B1 and prostate carcinoma.